Novo and Orbis strike $1.4B pact for ring-shaped drugs
Orbis Medicines, a Lilly-backed biotech, has entered a collaboration with Novo Nordisk worth up to $1.4 billion to develop macrocycles for cardiometabolic diseases. The deal focuses on ring-shaped molecules that combine advantages of antibodies and small-molecule drugs.
Orbis Medicines, a biotech with backing from Eli Lilly, has agreed to a collaboration with Novo Nordisk valued at up to $1.4 billion. The partnership centers on macrocycles—ring-shaped molecules that represent a distinct class of therapeutic agents. These compounds are positioned to merge the targeting precision of antibodies with the oral bioavailability and tissue penetration typical of small-molecule drugs.
The focus on cardiometabolic diseases places the deal within a high-priority therapeutic area, where large patient populations and chronic treatment needs drive substantial commercial interest. For Novo Nordisk, already a major player in metabolic conditions, the pact broadens its access to novel molecular formats. For Orbis, the agreement provides significant financial resources and validation of its platform from two major industry players.
This collaboration could accelerate the development of macrocycle-based therapies for cardiometabolic conditions, potentially offering patients new oral treatment options that combine convenience with targeted efficacy. If successful, such drugs may improve adherence and outcomes for chronic disease management. The deal also signals growing industry confidence in alternative molecular formats, which could reshape competitive dynamics and influence future investment in similar platforms.